Author: Capricorn Technologies GmbH

Capricorn’s latest publication Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets on the UniFluVec™ platform’s protective efficacy against the highly pathogenic H5N1 influenza virus in ferrets. The study demonstrates that a single intranasal dose of this replication-deficient attenuated influenza vector completely prevented mortality following H5N1 challenge, attributable to rapid and efficient viral…

We are pleased to highlight a significant new publication from Capricorn, entitled UniFluVec influenza vector induces heterosubtypic protection in ferrets after intranasal administration despite high attenuation.  This study explores the potential of the UniFluVec™ platform to confer protection against influenza virus of different subtype even when the vaccine is highly attenuated. Using the ferret model—a critical standard in influenza research—the authors demonstrate that…

Capricorn Technologies, together with its subsidiary NuCell GmbH (Tulln, Austria), has reached a significant milestone in the development of its new patented AEX-1 cells—an advanced Vero-derived cell line engineered for superior virus production efficiency and enhanced stability during cultivation. A defining feature of the AEX-1 cells is their consistently lower cytoplasmic pH, a trait that…

Capricorn Technologies GmbH has taken the next step in its development. By founding NuCell GmbH, it has expanded its research portfolio with a groundbreaking new product: AEX-1. The AEX-1 cell line was developed by co-culturing Vero cells with the amniotic membranes of chicken embryos in serum-free OptiPro medium. This innovative process has resulted in a…